Nicol V.
- Country
- The Netherlands
- Department
- Neurology
Research Overview
- Efficacy and Safety of Surlorian in Adults with Autosomal Dominant RYR1-Related Myopathy: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial
- Evaluation of Losmapimod's Safety, Tolerability, and Biomarker Impact in Facioscapulohumeral Muscular Dystrophy 1 (FSHD1) Patients
- A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)
Data & Insights
Has run more than one trial at 6 of 21 partner sites.
Specializations
Neuromuscular Disorders
This investigator specializes in the treatment and research of Facioscapulohumeral Muscular Dystrophy (FSHD), with particular focus on both FSHD1 and general FSHD variants.
- FSHD Disease Progression
- Long-term Treatment Approaches
- Muscular Function Assessment
The investigator's work encompasses comprehensive evaluation of therapeutic interventions for muscular dystrophy conditions.
Clinical Assessment
Expertise in evaluating biomarker analysis and conducting detailed clinical outcome assessments in neuromuscular conditions.
- Safety and Tolerability Studies
- Biomarker Evaluation
- Quantitative Strength Assessment
The research focus includes sophisticated measurement techniques for evaluating muscular strength and function.
Therapeutic Innovation
Specialized in investigating novel therapeutic approaches for progressive muscular disorders, particularly in chronic treatment protocols.
- Long-term Treatment Efficacy
- Disease Modification Strategies
- Treatment Response Monitoring
The investigator's work involves evaluating innovative therapeutic compounds for muscular dystrophy treatment.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.